Cannabigerol (CBG) is a cannabinoid derived from the cannabis plant, often dubbed the “mother of all cannabinoids” because it serves as a precursor to other compounds like cannabidiol (CBD) and tetrahydrocannabinol (THC). In the realm of veterinary medicine, CBG is gaining attention for its potential clinical applications in dogs and cats, particularly for managing conditions such as anxiety, pain, and inflammation. While research on CBG in pets is still emerging and less extensive than that on CBD, early findings suggest it may offer unique benefits due to its interactions with the endocannabinoid system (ECS),
a network in the body that regulates mood, pain, and inflammation, among other functions.
In dogs, CBG is being explored for its ability to alleviate pain and inflammation, especially in conditions like osteoarthritis. A study published in the Journal of the American Veterinary Medical Association investigated the effects of both CBD and CBG on dogs with
osteoarthritis and found that while both cannabinoids reduced pain and improved mobility, CBG appeared to have a more noticeable impact in some cases. This hints at its potential as a tool for managing chronic inflammatory conditions in canines. Beyond pain, CBG’s possible immune-supporting properties could also make it a candidate for addressing immune-mediated disorders or persistent inflammation in dogs.
For cats, the focus has leaned more toward CBG’s calming effects. A study in Frontiers in Veterinary Science examined its use in managing stress and anxiety in felines, revealing that CBG reduced stress-related behaviors and enhanced overall well-being. This anxiolytic effect might stem from CBG’s ability to influence the ECS and other systems, such as by inhibiting the uptake of gamma-aminobutyric acid (GABA), a neurotransmitter tied to relaxation, or by boosting levels of anandamide, often called the “bliss molecule” for its mood-enhancing properties.
What sets CBG apart from CBD or CBDA for treatments lies in their differing interactions with the body. Unlike CBD, which has a lower affinity for ECS receptors and acts more as a modulator, CBG binds more directly to both CB1 and CB2 receptors, potentially leading to stronger effects on processes like inflammation or pain relief.
Additionally, CBG’s ability to block serotonin receptors might increase serotonin levels, offering a mood-stabilizing edge that CBD doesn’t emphasize as much. Compared to CBDA, the acidic precursor to CBD found in raw hemp, CBG differs in absorption and retention. Studies show CBDA is absorbed 3 to 5 times more efficiently than CBD in dogs
and cats, which could make it faster-acting, but CBG’s distinct receptor activity and potential neurological benefits might make it preferable for conditions like anxiety or inflammation-driven pain.
When it comes to post-surgical pain, CBG’s effectiveness in dogs and cats remains understudied, but its anti-inflammatory and analgesic properties offer some promise. A preclinical study in the Journal of Pharmacology and Experimental Therapeutics showed CBG reducing inflammation in a mouse model of inflammatory bowel disease, suggesting it could help with inflammatory pain post-surgery. However, no specific studies have yet targeted CBG for post-surgical pain in pets.
In comparison, CBD has been tested more, with mixed results—one study on dogs after tibial plateau leveling osteotomy found no significant pain relief from CBD/CBDA compared to a placebo, while another suggested higher doses of CBD/CBDA might ease pain in dogs with intervertebral disc disease. Without direct evidence, it’s uncertain if
CBG outperforms CBD or other options for post-surgical pain in pets. For anxiety management, CBG might hold an edge. A study in Psychopharmacology observed anxiolytic effects in rats, where CBG reduced anxiety-like behaviors, possibly due to its GABA and anandamide interactions. The cat study in Frontiers in Veterinary Science further supports this, showing reduced stress behaviors. While CBD is widely used for pet anxiety with some success, CBG’s specific mechanisms could make it a compelling alternative, though more research is needed to confirm its superiority, especially in post-surgical contexts where anxiety often spikes.
Several studies provide a foundation for CBG’s use in pets, though the pool is small. The Journal of the American Veterinary Medical Association study on dogs with osteoarthritis highlighted CBG’s potential for pain and mobility improvement. The Frontiers in Veterinary
Science research on cats underscored its stress-reducing capabilities. A pharmacokinetic study in dogs found CBG to have a short half-life and be well-tolerated at 2 mg/kg twice daily, with its acidic form, CBGA, showing better absorption. A safety study also confirmed that 5 mg/kg of CBG daily was safe for dogs over 90 days, with no serious side effects noted.
In essence, CBG holds promise for treating pain, inflammation, and anxiety in dogs and cats, distinguished from CBD and CBDA by its receptor interactions and potential neurological effects. While it may prove effective for post-surgical pain and anxiety, the lack of targeted studies means it’s not yet clear if it’s more effective than other cannabinoids or conventional treatments.